A convivência com as plantas daninhas prejudica o acúmulo de nutrientes nas plantas de cenoura, porém, o mulch pode reduzir os efeitos da competição e proporcionar vantagens a cultura de interesse. ...Este trabalho objetivou avaliar o uso do mulch de palha de aveia-preta (Avena strigosa Schreb.) no acúmulo de massa seca de plantas daninhas e no acúmulo de nutrientes (N, P, K e S) nas plantas de cenoura da cultivar ‘Alvorada’. Os experimentos foram instalados nas estações de cultivo 2016/2017 e 2017/2018, em delineamento em blocos ao acaso em esquema fatorial 2 x 5, com 5 repetições. O primeiro fator correspondeu a cobertura do solo (com e sem mulch) e o segundo fator aos períodos de convivência com plantas daninhas (0, 15, 30, 60 e 120 dias após a emergência). A convivência com a comunidade infestante causou redução na absorção dos nutrientes e no acumulo de massa seca das raízes das plantas de cenoura, mais intensamente nos cultivos sem o mulch do que nos cultivos com mulch da palha de aveia preta. O uso do mulch pode reduzir em até 75.6% a massa seca das plantas daninhas durante todo o ciclo da cultura. Portanto, o uso de mulch de palha de aveia preta reduz a mato interferência e permite maior acúmulo de nutrientes e de biomassa nas raízes das plantas de cenoura da cultivar ‘Alvorada
We present a measurement of the forward-backward asymmetry in the production of B(±) mesons, A(FB)(B(±)), using B(±)→J/ψK(±) decays in 10.4 fb(-1) of pp̄ collisions at sqrts=1.96 TeV collected by ...the D0 experiment during Run II of the Tevatron collider. A nonzero asymmetry would indicate a preference for a particular flavor, i.e., b quark or ̄b antiquark, to be produced in the direction of the proton beam. We extract A(FB)(B(±)) from a maximum likelihood fit to the difference between the numbers of forward- and backward-produced B(±) mesons. We measure an asymmetry consistent with zero: A(FB)(B(±))=-0.24±0.41 (stat)±0.19 (syst)%.
Background:
Multiple myeloma (MM) is an incurable disease that is associated with severe symptoms affecting Health‐Related Quality of Life (HRQoL). Patients (pts) over 70 years of age may benefit ...less from new treatments (Tx) due to their heterogeneity and added comorbidity.
Aims:
Here, we report on the impact of new Tx on disease burden in terms of HRQoL and direct health costs as well as defined cut‐off points for GAH (Geriatric Assessment in Hematology) assessment.
Methods:
QoLMMBuS (NCT02946333) is an ongoing multicenter, prospective, observational study conducted at 53 Spanish sites in pts with MM who are not eligible for ASCT. Primary end points were HRQoL (baseline and 5 months), reported by: EQ‐5D (EuroQol) and QLQ C30/QLQ‐MY20 (EORTC) and direct health costs (inpatient hospitalization and diagnostic techniques). Secondary endpoints included demographic and baseline clinical characteristics, together with the classification of pts by the GAH scale performed at baseline (cut‐off point 42). Interim analysis with data cut‐off date: Nov 2018.
Results:
161 evaluable pts were enrolled between Nov 2016 and Oct 2018: median age (range) 77.6 (73.9–82.6) years, 44.7% male, ECOG 0/I 57.8%, stage II (R‐ISS) 41.6%, disease isotypes IgG, IgA 66.2% and 33.1%, respectively. High‐risk cytogenetics were detected in 18% of the pts: alterations in chromosome 1 (11.8%), del(17)(p13) (5%) and t(14;16)(q32;q23) (3.1%) were the most common. Renal failure was reported in 17.4% pts and cardiovascular and endocrine diseases were the most frequent comorbidities, 72.7% and 41.0%, respectively. Regarding GAH scale, the median score was 61.0 (31–84). Data for all domains were obtained from 74 pts; of these, 68.9% pts showed high probability of developing toxicity to the Tx (>42 points). A total of 156 pts received lenalidomide (32.0%) or bortezomib (68.0%) as a first line therapy. With a median follow‐up of 5.0 (3.5–11.1) months, the response rates were: CR 17.9%, PR 67.2%, SD 1.9% and PD 1.5%. 61.5% of pts remain on first line therapy. The median OS has not been reached. The analysis of changes from baseline through 5 months with EQ‐5D and QLQ C30 showed that pts had an increase in HRQoL‐mean values for the key domains of global health status/QoL, physical, role and emotional functioning over the course of Tx, although pts experienced a significant worsening in dyspnea domain (p = 0.003). The mean QLQ‐MY20 values showed a significant improvement for domains of disease symptoms (p = 0.037) and future perspective (p = 0.010) and a worsening in side effects of Txs and body image (Figure). Of the 156 pts, 56.4% experienced at least 1 adverse event. Of these, six (3.7%) pts reported at least one grade 3–4 toxicity. The most common reason for discontinuation was death in 24 pts. At the time of this analysis, 103 inpatient hospitalizations were reported with a mean time of 5 days/pt. Average costs/pt were 3,804.67 € (€2,653.98 Hematology unit + €1,150.69 other units). Mean direct costs of diagnosis per patient was €1,205.39.
Figure. Changes from baseline for EQ‐5D, EORTC QLQ‐C30 and QLQ‐MY20
Summary/Conclusion:
Lenalidomide and bortezomib were the two main drugs used in first line Tx of MM pts not eligible for ASCT. These preliminary analyses indicate that pts experienced a significant improvement in disease symptoms and future perspective and a significant worsening in dyspnea domains within the first months which have a lower impact on direct health costs over time. The efficacy and safety profile remained favorable at the time of analysis.
Objective:To investigate the potential antioxidant effects ofPhyllanthus niruri(P. niruri, Euphorbiaceae) tea on healthy subjects.Methods:Five non-smoking, male healthy volunteers, 20 to31 years old, ...were enrolled.Each subject was treated twice, following a randomized crossover fashion regarding the ingestion ofP. niruri infusion(5 g/750 mL)(tea group) or750 mL of water(control group).Fasting venous blood samples were collected prior to and at1,2 and4 h after infusion drinking.Samples were tested for plasmatic gallic acid and ascorbic acid levels, erythrocytic catalase and superoxide dismutase activities, and intracellularDCFH fluorescence in granulocytes, monocytes and lymphocytes.Results:Catalase and superoxide dismutase activities were not altered by tea ingestion.Plasma levels of gallic acid were significantly increasedat 1,2 and4 h afterP. niruri ingestion and plasma ascorbic acid at1 h afterP. niruri ingestion. Conclusions:Ingestion ofP. niruri tea is associated with a slight increase in antioxidant markers in human blood(ascorbic acid and gallic acid), which may contribute to its pharmacological effects.
Eslicarbazepine acetate is a novel sodium channel blocker for use in the treatment of focal onset seizures. Prospective studies on its effectiveness in monotherapy in patients with newly diagnosed ...partial epilepsy in routine clinical practice are scarce.
To evaluate the effectiveness of eslicarbazepine as initial monotherapy in patients with newly diagnosed partial epilepsy in routine clinical practice.
A prospective, multicentre, post-authorisation study. Patients with newly diagnosed partial epilepsy aged 18 years or older without previous treatment were included. The efficacy variables were: percentage of seizure-free patients, responders and reduction in monthly frequency of seizures. The safety variables analyse the 12-month retention rate and the occurrence of adverse effects.
Fifty-three patients were included. The retention rate was 77.4%. At the end of the observation period, 83% of patients were seizure-free and 92.5% had reduced their baseline frequency by 50% or more. In addition, 68% of the patients reported some adverse effect and 7.5% of them dropped out of the study for this reason. The effectiveness analysis of the subgroup of patients aged 65 years or more showed no differences with respect to the overall population.
Eslicarbazepine monotherapy in patients with newly diagnosed partial epilepsy, both in the general population and in the population over 65 years old, is effective and safe in routine clinical practice.
We present measurements of direct photon pair production cross sections using 8.5 fb$^{-1}$ of data collected with the D0 detector at the Fermilab Tevatron $p \bar p$ collider. The results are ...presented as differential distributions of the photon pair invariant mass $d\sigma/dM_{\gamma \gamma}$, pair transverse momentum $d \sigma /dp^{\gamma \gamma}_T$, azimuthal angle between the photons $d\sigma/d\Delta \phi_{\gamma \gamma}$, and polar scattering angle in the Collins-Soper frame $d\sigma /d|\cos \theta^*|$. Measurements are performed for isolated photons with transverse momenta $p^{\gamma}_T>18 ~(17)$ GeV for the leading (next-to-leading) photon in $p_T$, pseudorapidities $|\eta^{\gamma}|<0.9$, and a separation in $\eta-\phi$ space $\Delta\mathcal R_{\gamma\gamma} > 0.4$. We present comparisons with the predictions from Monte Carlo event generators {\sc diphox} and {\sc resbos} implementing QCD calculations at next-to-leading order, $2\gamma${\sc nnlo} at next-to-next-to-leading order, and {\sc sherpa} using matrix elements with higher-order real emissions matched to parton shower.
We present the first measurements of the ratios of cross sections σ(pp → Z+c jet)/σ(pp → Z+jet) and σ(pp → Z+c jet)/σ(pp → Z+b jet) for the associated production of a Z boson with at least one charm ...or bottom quark jet. Jets have transverse momentum pT(jet)>20 GeV and pseudorapidity |η(jet)|<2.5. These cross section ratios are measured differentially as a function of jet and Z boson transverse momenta, based on 9.7 fb(-1) of pp collisions collected with the D0 detector at the Fermilab Tevatron Collider at √s=1.96 TeV. The measurements show significant deviations from perturbative QCD calculations and predictions from various event generators.
We present the first combined measurement of the rapidity and transverse momentum dependence of dijet azimuthal decorrelations, based on the recently proposed quantity $R_{\Delta \phi}$. The variable ...$R_{\Delta \phi}$ measures the fraction of the inclusive dijet events in which the azimuthal separation of the two jets with the highest transverse momenta is less than a specified value for the parameter $\Delta \phi_{\rm max}$. The quantity $R_{\Delta \phi}$ is measured in $p\bar{p}$ collisions at $\sqrt{s}=1.96\,$TeV, as a function of the dijet rapidity interval, the total scalar transverse momentum, and $\Delta \phi_{\rm max}$. The measurement uses an event sample corresponding to an integrated luminosity of $0.7\,$fb$^{-1}$ collected with the D0 detector at the Fermilab Tevatron Collider. The results are compared to predictions of a perturbative QCD calculation at next-to-leading order in the strong coupling with corrections for non-perturbative effects. The theory predictions describe the data, except in the kinematic region of large dijet rapidity intervals and large $\Delta \phi_{\rm max}$.
Pregnancy registries provide trustworthy information about the risks associated to antiepileptic drugs (AEDs). EURAP is a Prospective International Registry which include patients who takes AEDs at ...the time of conception. The data of the Spanish centers which are contributing to EURAP reflects the reality of our milieu.
To study the incidence of major congenital malformations (MCM) /and/or fetal-perinatal death (MFP) and determine his relationship to AEDs in the Spanish EURAP registry.
After informed consent, patients were included in the prospective Registry and evaluated: at the beginning, at the end of the second and third trimester, after delivery and one year after birth. A variety of variables were collected: demographic, type of epilepsy, frequency of seizures during pregnancy, AEDs and dose, potential toxics, folate use and dose, obstetric complications and information of the newborn. After 6 years of recruitment (June 2001-October 2007) we analyzed the results of this Registry in Spain with special attention on the incidence of major congenital malformations and foetal-perinatal death.
Of a whole of 540 cases included in the Registry, 490 were prospective (included before the 16th week), of these we had complete information in 368 cases. Major congenital maLformations were present in 5% (n=13) of the child exposed to monotherapy and 12% (n=6) of those exposed to polytherapy (p=0.08). All polytherapy combinations with MCM, contained valproate. Of the variables analyzed only low weight at birth and the AEDs used showed statistically significant association with MCM and MFP. The percentage of MCM was superior for valproate, particularly at doses equal or superior of 1000 mg/day (16%), although differences were not statistically significant. The majority of ours patients were on monotherapy (83%) with AEDs at low doses and were taking 5 mg of folate.
Patients on polytherapy, particularly those with valproate in combination present more risk of MCM. For monotherapy exposures only weight at birth and the AEDs used have association statistically significant with MC/MFP. Valproate in our series presents more risk than lamotrigine and does not show differences with regard to carbamazepine.
We present measurements of the differential cross section $d\sigma/dp_{T}^{\gamma}$ for the associated production of a $c$-quark jet and an isolated photon with rapidity $|y^{\gamma}|< 1.0$ and ...transverse momentum $30 < p_{T}^{\gamma} < 300$ GeV. The $c$-quark jets are required to have $|y^{jet}| < 1.5$ and $p_{T}^{jet} >15$ GeV. The cross section ratios $\sigma(\gamma+c)/\sigma(\gamma+b)$ as a function of $p_{T}^{\gamma}$ are also presented. The results are based on data corresponding to an integrated luminosity of 8.7 fb$^{-1}$ recorded with the D0 detector at the Fermilab Tevatron $p\bar{p}$ Collider at $\sqrt{s}=$1.96 TeV. The obtained results are compared to next-to-leading order perturbative QCD calculations using various parton distribution functions, to predictions based on the $k_{T}$-factorization approach, and to predictions from the Sherpa and Pythia Monte Carlo event generators.
PDF
